Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Biotech innovation stories

Nov 16, 2026

Sofinnova Partners raises €725M crossover fund for late-stage European biotechs

Paris-based Sofinnova Partners secured €725 million ($815 million) for its second crossover fund targeting late-stage European biopharma companies, addressing a financing gap in the sector.

Nov 16, 2026·3 sources
00
Nov 15, 2026

J&J in talks to acquire eye disease biotech for up to $3.4bn

Johnson & Johnson is poised to acquire a privately held eye disease drug developer in a deal valued at up to $3.4 billion, according to the Financial Times.

Nov 15, 2026·2 sources
00

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Nov 13, 2026

Windward Bio prices $175M IPO to advance China-licensed lung drugs

Swiss immune drug developer Windward Bio raised $175 million in its IPO, the biotech sector's 30th listing of the year, to advance lung disease drugs licensed from China.

Nov 13, 2026·2 sources
00
Nov 10, 2026

Beam Therapeutics base-editing sickle cell therapy succeeds in pivotal trial

Beam Therapeutics announced its base-edited sickle cell therapy met its primary endpoint in a Phase 1/2 clinical trial, potentially positioning it as a third one-time curative therapy for the disease.

Nov 10, 2026·2 sources
00

AstraZeneca acquires vaccine biotech Omniose to bolster pipeline

AstraZeneca acquired early-stage US biotech Omniose, which is developing vaccines against serious bacterial infections, integrating it into its infectious diseases division.

Nov 10, 2026·2 sources
00
Nov 5, 2026

Alethio Therapeutics raises $90M Series A for rare blood cancer antibody

Oxford spinout Alethio Therapeutics secured $90 million in Series A funding to advance an antibody treatment for myeloproliferative neoplasms, a group of rare blood cancers.

Nov 5, 2026·2 sources
00
Nov 2, 2026

Cerus blood-safety system meets primary endpoint in late-stage trial

Cerus Corp announced that red blood cells treated with its blood-safety technology performed as well as conventional red blood cells in patients requiring transfusions in a late-stage study.

Nov 2, 2026·2 sources
00
Oct 30, 2026

First patient receives Sumitomo Pharma stem cell transplant for Parkinson's disease

A patient has undergone pioneering stem-cell therapy to treat Parkinson's disease using Sumitomo Pharma's treatment, which involves transplanting millions of induced pluripotent stem (iPS) cells. This marks a world first following the treatment's conditional approval in Japan.

Oct 30, 2026·3 sources
00
Oct 29, 2026

KAIST researchers develop GB2Ab antibody to treat cancer cachexia in mice

A research team at KAIST has developed GB2Ab, a therapeutic antibody candidate that blocks signals responsible for appetite suppression, weight loss, and muscle wasting in cancer cachexia. The antibody successfully reversed weight and muscle loss in mouse models.

Oct 29, 2026·2 sources
00
Oct 28, 2026

IAVI receives up to $99 million US contract for Ebola vaccine development

Biomedical research organization IAVI was awarded $36 million under a US government contract worth up to $99 million to advance development of its single-dose Ebola vaccine.

Oct 28, 2026·2 sources
00
Oct 27, 2026

Artiva discontinues cell therapy after two patient deaths, cuts workforce by 94%

Artiva Biotherapeutics halted development of its experimental cell therapy for autoimmune conditions following two patient deaths in clinical trials and announced massive workforce reductions.

Oct 27, 2026·4 sources
00
Oct 23, 2026

Tegoprubart outperforms tacrolimus in preserving kidney function after transplant, BESTOW trial finds

The Phase 2 BESTOW clinical trial demonstrated that tegoprubart, a novel anti-CD40L antibody therapy, was superior to tacrolimus, the current standard of care, at preserving kidney function in adults receiving their first kidney transplant. The trial results suggest a potential advancement in immunosuppressive treatment regimens for transplant patients.

Oct 23, 2026·3 sources
00

Roche licenses Zymeworks' experimental lung cancer drug ZW209 in deal worth up to $813 million

Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.

Oct 23, 2026·5 sources
00
Oct 22, 2026

Gilead acquires PepStar inflammation drug program for $1.28 billion

Gilead Sciences will acquire PepStar Therapeutics' oral inflammation drug program, including an experimental IL-23 receptor inhibitor for inflammatory bowel disease, for $1.28 billion upfront in a deal that could compete with Johnson & Johnson's new immunology pill.

Oct 22, 2026·3 sources
00
Oct 19, 2026

Disc Medicine's erythropoietic protoporphyria drug succeeds in late-stage trial

Disc Medicine's experimental pill for erythropoietic protoporphyria, a rare disease causing extreme pain from sunlight, met all primary and secondary goals in a late-stage trial, sending shares surging.

Oct 19, 2026·2 sources
00
Sep 21, 2026

Beacon Therapeutics' gene therapy succeeds in phase 2 trial for rare inherited eye disease

Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.

Sep 21, 2026·2 sources
00
Sep 14, 2026

Scholar Rock's spinal muscular atrophy drug Isembyld approved by FDA

The FDA approved Isembyld (apitegromab), the first muscle-targeted treatment for spinal muscular atrophy. The drug will cost approximately $310,000 annually and showed improvements in motor function in clinical trials.

Sep 14, 2026·3 sources
00
Aug 26, 2026

RevMed's pancreatic cancer pill daraxonrasib wins FDA approval at $475,000 annual cost

Revolution Medicines' breakthrough pill targeting KRAS mutations in advanced pancreatic cancer received FDA approval, priced at over $475,000 per year. The drug nearly doubles survival in patients with this hard-to-treat cancer.

Aug 26, 2026·2 sources
00

Biohaven licenses epilepsy drug platform to SK Biopharmaceuticals for up to $795 million

Biohaven Pharmaceuticals has entered into a licensing agreement with South Korean drugmaker SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, in a deal worth up to $795 million.

Aug 26, 2026·2 sources
00
Aug 20, 2026

Ultragenyx wins first gene therapy approval with Genglycos for glycogen storage disease

The FDA approved Ultragenyx's Genglycos gene therapy for a rare glycogen storage disease, marking the company's first gene therapy clearance and providing a priority review voucher.

Aug 20, 2026·4 sources
00
Jun 30, 2026

FDA Approves Orca Bio's TREGZI as First Precision-Engineered Cell Therapy for Blood Cancer Transplants

The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.

Jun 30, 2026·7 sources
00

Top claims

  • ▪Sofinnova Crossover II has already deployed capital into clinical-stage biotechnology companies CellCentric and Hemab Therapeutics
  • ▪Sofinnova Partners partner Kinam Hong led an initial investment in immune drugmaker Abivax, which later reached a public market valuation of approximately $7 billion
  • ▪Sofinnova Partners partner Kinam Hong stated that Europe faces a scale-up financing problem rather than an innovation problem for life sciences companies

Subtopics

Clinical trials10Drug development9Drug Policy, Pricing & Approval8Pharmaceutical Industry7Drug Approval and Clinical Trials6Cancer & Oncology5FDA drug approval4Mergers & acquisitions (M&A)4Biotechnology3Cancer treatment3Gene therapy3Mergers and acquisitions3Venture capital funding3Autoimmune disease treatments2Biotech startup2Cancer treatment breakthroughs2Clinical trial endpoints2Corporate strategy2FDA regulatory approval2Hematology2Immunology2Neurodegenerative disease2Vaccine development2Alzheimer’s & dementia1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories